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Background: Both BRCA1 and epidermal growth factor receptor (EGFR) play a critical role in ovarian cancer progression.
However, the crosstalk between BRCA1 and EGFR signaling pathways in ovarian cancer remains largely unknown.
Methods: The effect of BRCA1 on EGFR was assessed in 146 serous ovarian cancer patients (28 pairs of BRCA1-mutated
or not, 23 pairs of BRCA2-mutated or not, and 22 pairs with hypermethylated BRCA1 promoter or not). BRCA1 promoter
methylation was analyzed by bisulfite sequencing using primers flanking the core promoter region. Expression levels
of BRCA1 and EGFR were assessed by immunohistochemistry and real-time PCR. The knockdown and overexpression of
BRCA1 were achieved using a lentiviral vector in 293 T cells, SKOV3 ovarian cancer cells, and primary non-mutated and
BRCA1-mutated ovarian cancer cells.
Results: EGFR expression was increased in all cancer tissues compared to normal tissues. Additionally, EGFR expression
was higher in normal tissues of BRCA1-mutated patients, and was further increased in cancer tissues; EGFR levels were
also significantly elevated in ovarian cancer with promoter hypermethylation-mediated inactivation of BRCA1. BRCA1
knockdown was an effective way to activate EGFR expression in ovarian cancer cells.
Conclusions: These results indicate that BRCA1 may be a potential trigger in transcriptional regulation of EGFR in the
development of ovarian cancer.
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Ovarian cancer is characterized by a high rate of mortal-
ity among gynecologic oncology patients [1]. To date, al-
though the exact cause of ovarian cancer remains largely
unknown, BRCA mutations are known hereditary fac-
tors, and the risk of ovarian cancer conferred by BRCA
mutations can be regulated by both genetic and environ-
mental components [2]. The epidermal growth factor
receptor (EGFR) is a member of the ErbB family of re-
ceptor tyrosine kinases that exert a direct effect on ovar-
ian cell proliferation, migration, and invasion, as well as
angiogenesis [3]. The overexpression of EGFR frequently
occurs in ovarian cancer tissues [3,4] and correlates with
poor prognosis of the patients [5,6]. Notably, emerging
evidence has established that: (i) EGFR is a potential
link between genetic and environmental interactions [7];* Correspondence: leeda@ymail.com; yangq@sj-hospital.org
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stated.(ii) EGFR and BRCA1 can be found in the same protein
complex, and convergence exists between EGFR- and
BRCA1-related signaling pathways [8,9]; and (iii) BRCA1
mutations are vulnerable to the development of EGFR-
positive cancers [10]. Therefore, insights into the com-
plex interrelationship between BRCA and EGFR might
improve our understanding of the basic molecular mech-
anism of ovarian cancer. For this reason, the present study
was undertaken to investigate EGFR expression after
BRCA inactivation events (mutation, promoter methyla-
tion, or knockdown), and to provide novel insights into
the regulatory mechanism of EGFR.Methods
Patients and tissue collection
This study was approved by the Institutional Review
Board at China Medical University. Serous ovarian can-
cer patients (28 pairs of BRCA1-mutated or not, 23 pairs
of BRCA2-mutated or not, and 22 pairs with hypermethy-
lated BRCA1 promoter or not) were enrolled betweenhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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Fresh tumor samples, adjacent normal ovarian tissues,
ascites, and blood samples were obtained at the time
of primary surgery before any chemotherapy or radio-
therapy. Hematoxylin and eosin staining of the samples
for histopathological diagnosis and grading were per-
formed by three staff pathologists using the World
Health Organization criteria. All patients were screened
for BRCA1 and 2 mutations by multiplex polymerase
chain reaction (PCR) with complete sequence analysis, as
previously reported [11]. Their characteristics are given
in Additional file 1.
Cell culture and lentiviral transfection
Primary ovarian cancer cells were obtained from the
ascites of patients undergoing surgery for ovarian cancer
and cultured in RPMI 1640 with 10% fetal bovine serum
(Invitrogen, CA, USA) as described previously [12]. Hu-
man 293 T cells and SKOV3 ovarian cancer cells were
maintained in DMEM with 10% fetal bovine serum
(Invitrogen). Lentiviral vectors expressing short hairpin
RNAs (shRNAs) against BRCA1 (NM_007299) were
obtained from Genechem Co., Ltd (Shanghai, China),
and synthesized as follows: forward, 5′-CCGGAACCT
GTCTCCACAAAGTGTGCTCGAGCACACTTTGTGG
AGACAGGTTTTTTTG-3′, and reverse, 5′-AATTC
AAAAAAACCTGTCTCCACAAAGTGTGCTCGAGCA
CACTTTGTGGAGACAGGTT-3′. The non-silencing
shRNA sequence was used as a negative control and
synthesized as follows: forward, 5′-ccggTTCTCCGA
ACGTGTCACGTctcgagACGTGACACGTTCGGAGAA
tttttg-3′, and reverse, 5′-aattcaaaaaTTCTCCGAACG
TGTCACGTctcgagACGTGACACGTTCGGAGAA-3′.
For overexpression of BRCA1, the open reading frame of
BRCA1 (NM_007299) was cloned into the lentiviral vec-
tor GV287 (Ubi-MCS-3FLAG-SV40-EGFP) (Genechem).
Transfections were performed using polybrene and en-
hanced infection solution (Genechem) according to the
manufacturer’s recommended protocol.
Real-time PCR and immunohistochemical analysis
Real-time PCR and immunohistochemistry were per-
formed as previously described [11]. The specific primer
sequences for real-time PCR were as follows: EGFR, 5′-
GCGAATTCCTTTGGAAAACC-3′ (F) and 5′- AAGG
CATAGGAATTTTCGTAGTACA-3′ (R); BRCA1, 5′-
GGCTATCCTCTCAGAGTGACATTT-3′ (F) and 5′-GC
TTTATCAGGTTATGTTGCATGG-3′ (R); GAPDH, 5′-
AGGTGAAGGTCGGAGTCA-3′ (F) and 5′-GGTCATT
GATGGCAACAA-3′(R). The primary antibody for immu-
nohistochemistry was rabbit anti-EGFR of human origin
(1:250; Santa Cruz Biotechnology, CA, USA). Immu-
nostaining was evaluated by two independent pathol-
ogists, blinded to the identity of subject groups. Areaquantification was performed with a light microscope at a
magnification of 400× and analyzed by Image-Pro Plus 6.0
(Media 2 Cybernetics, USA). The intensity of staining was
divided into 10 units.
Bisulfite sequencing
Genomic DNA extracted from ovarian cancer and nor-
mal ovarian tissue with a TIANamp Genomic DNA kit
(Tiangen Biotech, Beijing, China) was subjected to bisul-
fite conversion using the EZ DNA Methylation-Direct kit
(Zymo Research, Orange, USA) following the manufac-
turer’s instructions. The conversion efficiency was esti-
mated to be at least 99.6%. The DNA was then amplified
by nested PCR. After gel purification, cloning, and trans-
formation into Escherichia coli Competent Cells JM109
(Takara, Tokyo, Japan), 10 positive clones of each sample
were sequenced to ascertain the methylation patterns of
each CpG locus. The following primers were used: round I,
5′-TTGTAGTTTTTTTAAAGAGT-3′ (F) and 5′-TACT
ACCTTTACCCAAAACAAAA-3′ (R); and round II, 5′-
GTAGTTTTTTTAAAGAGTTGTA-3′ (F) and 5′-ACC
TTTACCCAAAACAAAAA-3′ (R). The conditions were
as follows: 95°C for 2 min, 40 cycles of 30 s at 95°C, 30 s at
56°C, and 45 s at 72°C, then 72°C for 7 min.
Statistical analysis
The data are presented as mean ± standard deviation
(SD). Statistical differences in the data were evaluated
by a Student’s t-test or one-way analysis of variance
(ANOVA) as appropriate, and were considered sig-
nificant at P < 0.05.
Results
Differences in expression patterns of EGFR in non-mutated
and BRCA1- or BRCA2-mutated ovarian cancer
Real-time PCR and immunohistochemical analysis showed
that the levels of EGFR mRNA and protein were increased
in non-mutated and BRCA1-mutated ovarian cancer com-
pared with their adjacent normal tissue. It is interesting
to note that BRCA1-mutated ovarian cancer showed
dramatically increased expression of EGFR compared
with the remaining three groups (Figure 1A and B).
However, although the levels of EGFR mRNA and protein
were increased in non-mutated and BRCA2-mutated ovar-
ian cancer compared with their adjacent normal tissue,
there was no significant difference in the expression of
EGFR between the non-mutated and BRCA2-mutated
groups, including ovarian cancer and normal ovarian
tissue (Figure 1C and D).
Reduced expression of BRCA1 mediated by BRCA1 promoter
hypermethylation is inversely correlated with EGFR levels
In mammals, promoter methylation is an epigenetic


























































































































































Figure 1 EGFR expression patterns in non-mutated and BRCA1- or BRCA2-mutated ovarian cancer. A and C, relative EGFR mRNA levels
were measured in non-mutated and BRCA1- or BRCA2-mutated ovarian cancer, and their adjacent normal tissue. Bar graphs show mean ± SD.
B and D, EGFR protein levels assessed by immunohistochemistry in non-mutated and BRCA1- or BRCA2-mutated ovarian cancer, and their
adjacent normal tissue. The intensity of staining was divided into 10 units.
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tissue with a hypermethylated BRCA1 promoter (Figure 2B
and D, P < 0.05) displayed reduced expression of BRCA1
(Figure 2E, P < 0.05) compared with adjacent normal
tissue. However, no significant BRCA1 expression dif-
ferences (Figure 2H, P > 0.05) were observed in ovar-
ian cancer with an unmethylated BRCA1 promoter
(Figure 2C and G, P > 0.05) compared with adjacent
normal tissue. Based on these considerations, the low
levels of BRCA1 mediated by promoter hypermethyla-
tion was an appropriate model for investigating the
physiological relationship between BRCA1 and EGFR.
Notably, the expression levels of EGFR were markedlyincreased (Figure 2F, P < 0.05), along with a hypermethy-
lated promoter-mediated BRCA1 deficiency in ovarian
cancer (Figure 2E, P < 0.05). However, although the ex-
pression of EGFR was also increased in ovarian cancer
tissue (Figure 2I, P < 0.05) along with no significant dif-
ference in BRCA1 promoter methylation or expression
(Figure 2G and H, P > 0.05), the increased levels of EGFR
was not significant compared with ovarian cancer with
BRCA1 deficiency.
BRCA1 can regulate EGFR expression in ovarian cancer cells
To further confirm the role of BRCA1 in the regulation
of EGFR, the effects of overexpression or knockdown of




































































































































































Figure 2 EGFR expression patterns in ovarian cancer with hypermethylated promoter-mediated BRCA1 inactivation. A, the location of
CpG sites in the core promoter region of the BRCA1. Genomic coordinates are shown, along with the primer-amplified fragments, GC percentage,
location of individual CpG dinucleotides (dashes), and BRCA1 RefSeq gene (exon 1 is shown as a blue box and the intron is shown as an
arrowed line). The arrow indicates the direction of transcription. B and C, comparative analysis of methylation patterns in the core promoter
region of BRCA1 in ovarian cancer and adjacent normal tissue. The circles correspond to the CpG sites denoted by black dashes in A. Closed
circles, methylation; open circles, unmethylated. Ten individual clones were sequenced for each sample. D and G, summary of the methylation
levels of BRCA1 core promoter from the measurements shown in B and C, respectively. E and H, relative BRCA1 mRNA levels were measured in
ovarian cancer with identified hypermethylated or unmethylated BRCA1 promoter, compared with their adjacent normal tissue. F and I,
relative EGFR mRNA levels were measured in ovarian cancer with identified BRCA1 inactivation or not, respectively. Bar graphs show mean ± SD.
* P < 0.05 vs. normal.
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cancer cell line SKOV3, and primary ovarian cancer cells
with identified BRCA1 mutations or no BRCA1 muta-
tions. The results indicated that there were no signi-
ficant changes in the expression of EGFR after the
overexpression or knockdown of BRCA1 in 293 T cells
(Figure 3A). Interestingly, we observed that the knockdown
of BRCA1 was an effective way to induce an increase
of EGFR levels in SKOV3 and non-BRCA1-mutatedovarian cancer cells (Figure 3B and C). In addition,
the overexpression of BRCA1 can effectively reduce the
expression of EGFR in BRCA1-mutated ovarian cancer
cells (Figure 3D).
Discussion
In this study, we report an association between BRCA1
and EGFR status in ovarian cancer cells: (i) although








































































































Figure 3 Effects of BRCA1 on EGFR expression. A–D, relative EGFR mRNA levels after the overexpression or knockdown of BRCA1 in 293 T
cells, human SKOV3 ovarian cancer cells, and primary non-mutated and BRCA1-mutated ovarian cancer cells. Bar graphs show mean ± SD. * P< 0.05 vs.
normal. Sh, short hairpin RNAs; Op, overexpression.
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exhibited dramatically increased expression of EGFR com-
pared with the non-BRCA1-mutated group; (ii) BRCA1
inactivation (BRCA1 mutation or promoter hyperme-
thylation) dramatically increased the expression of EGFR;
and (iii) BRCA1 knockdown was an effective way to acti-
vate the EGFR gene. These results suggest that BRCA1
may be a potential regulator of EGFR in ovarian cancer,
although a similar phenomenon has even been observed
in breast cancer [14]. It appears that BRCA1 rather
than BRCA2 may be a potential regulator of EGFR
expression. In agreement with these findings, Nisman
suggested that the concentration of soluble EGFR was
significantly higher in women with BRCA1 mutations
than in controls and women with BRCA2 mutations
[8]. Interestingly, the activation effect due to the loss of
BRCA1 was primarily observed in cells originating from
ovarian cancer, while 293 T cells were insensitive to the
overexpression or knockdown of BRCA1. Hence, the
induced expression of EGFR was likely to be the result
of a complex interaction of special factors in ovarian can-
cer cells. Notably, several studies suggest that BRCA1
haploinsufficiency is more likely to become cancerous
compared with the non-BRCA1-mutated group, due to
an extraordinary ability for clonal growth and prolifera-
tion [15]. EGFR also plays an important role in regulat-
ing cell proliferation and resistance to cell apoptosis
during cancer development [3]. As shown in Additional
file 2 (methods shown in Additional file 3), BRCA1
knockdown-mediated EGFR overexpression is associ-
ated with increased proliferation, and proliferative ef-
fects were reversed by the EGFR inhibitor erlotinib.
Moreover, patients with low BRCA1-related high levels
of EGFR showed a trend for poor survival (Additionalfile 4, methods shown in Additional file 3). Therefore,
it can be predicted that BRCA1 inactivation-related
high levels of EGFR may be involved in promoting
ovarian cancer progression. To date, it is not fully
understood how BRCA1 represses EGFR gene expres-
sion at the molecular level. However, is it possible that
the repression takes place at the transcriptional level?
Some insight was gained by a study demonstrating that
BRCA1 is an important transcriptional regulator, which
modulates the translational efficiency of approximately
7% of the mRNAs expressed in human breast cancer cell
line MCF-7 [16]. A growing body of evidence suggests
that BRCA1 has extensive cellular effects on hormone
receptor signaling pathways. For example, BRCA1 can
inhibit progesterone receptor (PR) activity in the PR-
positive human breast cancer cell line T47D [17,18] and
repress estrogen receptor-alpha activity in MCF-7 cells
[19]. BRCA1 may also be a potential regulator of the
insulin-like growth factor 1 receptor in human breast
cancer cell line HCC1937 [20]. However, to date, there
have been few reports about the interactions between
BRCA1 and EGFR in ovarian cancer.
Conclusions
The present study supports the theory that the EGFR
gene is also a physiologically relevant downstream target
for BRCA1. The data presented in this study emphasize
the convergence of the EGFR-mediated cell proliferation
pathway and BRCA1-mediated antitumor mechanism.
Clarifying the complex interactions between BRCA1 and
EGFR signaling pathways at the transcriptional, posttran-
scriptional, and epigenetic levels may improve our under-
standing of the basic molecular mechanism of ovarian
cancer.
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Additional file 1: Table S1. Clinical characteristics for the 28 BRCA1-
mutated serous ovarian cancer patients. Table S2: Clinical characteristics
for the 23 BRCA2-mutated serous ovarian cancer patients.
Additional file 2: Cell proliferation after the overexpression of
BRCA1, or knockdown of BRCA1 plus erlotinib or not.
Additional file 3: Supplementary methods.
Additional file 4: Univariate analysis of overall survival for ovarian
cancer patients with low BRCA1-high EGFR expression and high
BRCA1-low EGFR expression.
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